Affordable Access

Publisher Website

Comparative bioavailability of ceftibuten in capsule and suspension forms

Authors
Journal
Clinical Therapeutics
0149-2918
Publisher
Elsevier
Publication Date
Volume
18
Issue
6
Identifiers
DOI: 10.1016/s0149-2918(96)80068-3
Disciplines
  • Pharmacology

Abstract

Abstract The comparative bioavailability of ceftibuten, a new third-generation cephalosporin antibiotic given orally once daily, in capsule and suspension dosage forms, was assessed in healthy male subjects. In three separate studies, subjects received either a 400-mg dose as a suspension or one laboratory-batch, 400-mg capsule; one laboratory-batch, 400-mg capsule or two laboratory-batch, 200-mg capsules; or one production-batch, 400-mg capsule or two laboratory-batch, 200-mg capsules. Plasma samples were assayed for ceftibuten using high-performance liquid chromatography, and the data were assessed using pharmacokinetic and statistical methods. Confidence intervals for the maximum plasma concentration and the area under the plasma concentration—time curve extrapolated to infinity were within 80% to 125% of guidelines, demonstrating the bioequivalence of the two treatments within each of the three studies. One 400-mg capsule (laboratory or production batch) was bioequivalent to two 200-mg capsules used in a clinical efficacy trial; the 400-mg suspension was bioequivalent to a 400-mg capsule (laboratory batch). Thus we concluded that the capsule and the suspension dosage forms were bioequivalent.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Bioavailability of potassium from three dosage for...

on Journal of clinical pharmacolo... November 1988

[Comparative bioavailability of ampicillin after a...

on Journal de pharmacie de Belgiq... 1981

Comparative bioavailability of S-carboxymethylcyst...

on Biopharmaceutics & drug dispos... 1982
More articles like this..